Cochlear's Fiscal H1 Results Miss 'Disappointing,' Jarden Research Says

MT Newswires Live

Feb 17, 2025

Cochlear (ASX:COH) first half-results missing estimates is "disappointing" due to upgrades to its Nuclear 8 sound processor, which caused a decline in services revenue, according to Feb. 14 noted by Jarden Research.

The company reported Friday that its six-month earnings per diluted share rose to AU$3.125 from AU$2.913 per diluted share a year earlier. Total revenue for the half year ended Dec. 31, 2024, was AU$1.17 billion.

Jarden believes that COH's plan to launch its next-generation implant and the introduction of its Kanso 3 sound processor by mid-2025 should strengthen its outlook for 2026.

The investment firm reaffirmed a neutral rating and a price target of AU$263.75 on COH.

Shares of COH rose 4% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2512996179"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512996179\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512996179?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-17 12:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512996179","market":"us","top_or_hot":-1,"title":"Cochlear's Fiscal H1 Results Miss 'Disappointing,' Jarden Research Says","media":"MT Newswires Live","content":"<html><body><p> Cochlear (ASX:COH) first half-results missing estimates is \"disappointing\" due to upgrades to its Nuclear 8 sound processor, which caused a decline in services revenue, according to Feb. 14 noted by Jarden Research.</p><p>The company reported Friday that its six-month earnings per diluted share rose to AU$3.125 from AU$2.913 per diluted share a year earlier. Total revenue for the half year ended Dec. 31, 2024, was AU$1.17 billion.</p><p>Jarden believes that COH's plan to launch its next-generation implant and the introduction of its Kanso 3 sound processor by mid-2025 should strengthen its outlook for 2026.</p><p>The investment firm reaffirmed a neutral rating and a price target of AU$263.75 on COH.</p><p>Shares of COH rose 4% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear's Fiscal H1 Results Miss 'Disappointing,' Jarden Research Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear's Fiscal H1 Results Miss 'Disappointing,' Jarden Research Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-17 12:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cochlear (ASX:COH) first half-results missing estimates is \"disappointing\" due to upgrades to its Nuclear 8 sound processor, which caused a decline in services revenue, according to Feb. 14 noted by Jarden Research.</p><p>The company reported Friday that its six-month earnings per diluted share rose to AU$3.125 from AU$2.913 per diluted share a year earlier. Total revenue for the half year ended Dec. 31, 2024, was AU$1.17 billion.</p><p>Jarden believes that COH's plan to launch its next-generation implant and the introduction of its Kanso 3 sound processor by mid-2025 should strengthen its outlook for 2026.</p><p>The investment firm reaffirmed a neutral rating and a price target of AU$263.75 on COH.</p><p>Shares of COH rose 4% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COH.AU","symbol_name":"COCHLEAR LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2512996179","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512996179","pubTimestamp":1739765462,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cochlear  first half-results missing estimates is \"disappointing\" due to upgrades to its Nuclear 8 sound processor, which caused a decline in services revenue, according to Feb. 14 noted by Jarden Research.The company reported Friday that its six-month earnings per diluted share rose to AU$3.125 from AU$2.913 per diluted share a year earlier. Total revenue for the half year ended Dec. 31, 2024, was AU$1.17 billion.Jarden believes that COH's plan to launch its next-generation implant and the introduction of its Kanso 3 sound processor by mid-2025 should strengthen its outlook for 2026.The investment firm reaffirmed a neutral rating and a price target of AU$263.75 on COH.Shares of COH rose 4% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COH.AU":"COCHLEAR LTD","BK7007":"医疗保健设备"},"translate_title":"Jarden Research表示，科利耳上半年财报业绩“令人失望”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":1},"content_text":"Cochlear (ASX:COH) first half-results missing estimates is \"disappointing\" due to upgrades to its Nuclear 8 sound processor, which caused a decline in services revenue, according to Feb. 14 noted by Jarden Research.The company reported Friday that its six-month earnings per diluted share rose to AU$3.125 from AU$2.913 per diluted share a year earlier. Total revenue for the half year ended Dec. 31, 2024, was AU$1.17 billion.Jarden believes that COH's plan to launch its next-generation implant and the introduction of its Kanso 3 sound processor by mid-2025 should strengthen its outlook for 2026.The investment firm reaffirmed a neutral rating and a price target of AU$263.75 on COH.Shares of COH rose 4% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}